OCGN vs. NVAX

In the year-to-date period, OCGN achieves a 3.86% return, which is significantly higher than NVAX's -8.71% return. Over the past 10 years, OCGN has underperformed NVAX with an annualized return of -47.15%, while NVAX has yielded a comparatively higher -27.29% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Ocugen, Inc. (OCGN) and Novavax, Inc. (NVAX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current OCGN Sharpe Ratio is -0.61, which is comparable to the NVAX Sharpe Ratio of -0.55. The chart below compares the historical Sharpe Ratios of OCGN and NVAX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither OCGN nor NVAX has paid dividends to shareholders.

The maximum OCGN drawdown since its inception was -99.97%, roughly equal to the maximum NVAX drawdown of -98.82%. Use the drawdown chart below to compare losses from any high point for OCGN and NVAX.

The current volatility for Ocugen, Inc. (OCGN) is 21.40%, while Novavax, Inc. (NVAX) has a volatility of 27.71%. This indicates that OCGN experiences smaller price fluctuations and is considered to be less risky than NVAX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Ocugen, Inc. and Novavax, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.